The FDA has approved elinzanetant, a new drug for menopausal hot flashes and night sweats that may also help with menopause-related sleep problems. Significant news for patients who can't take estrogen; nonhormonal treatments have been very limited.
F.D.A. Approves New Menopause Drug
www.nytimes.com
October 24, 2025 at 5:10 PM
The FDA has approved elinzanetant, a new drug for menopausal hot flashes and night sweats that may also help with menopause-related sleep problems. Significant news for patients who can't take estrogen; nonhormonal treatments have been very limited.
For those looking for potential solutions to menopause and sleep. Very small effect size
Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study academic.oup.com/sleep/articl...
Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study academic.oup.com/sleep/articl...
Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study
Menopausal sleep disturbances are common and disruptive, with a high unmet need due to their unique etiology and absence of specific treatments. NIRVANA is
academic.oup.com
August 1, 2026 at 10:25 PM
For those looking for potential solutions to menopause and sleep. Very small effect size
Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study academic.oup.com/sleep/articl...
Elinzanetant in postmenopausal women with sleep disturbance: results from the randomized, phase II NIRVANA study academic.oup.com/sleep/articl...
Elinzanetant: Ohne Hormone gegen Hitzewallungen | Ausgabe vom 21.08.2026
#DerApotheker 🥷 1
#DerApotheker 🥷 1
August 20, 2026 at 6:06 PM
Elinzanetant: Ohne Hormone gegen Hitzewallungen | Ausgabe vom 21.08.2026
#DerApotheker 🥷 1
#DerApotheker 🥷 1
#DragiWebdo n°495 : Infertilité, hypothyroïdie, H.Pylori/aspirine, dépistage CCR, grossesse/risque TDM, élinzanetant, gale
www.medicalement-geek.com/2025/09/drag...
www.medicalement-geek.com/2025/09/drag...
Dragi Webdo n°495 : Infertilité, hypothyroïdie, H.Pylori/aspirine, dépistage CCR, grossesse/risque TDM, élinzanetant, gale
Dragi Webdo n°495 : Infertilité, hypothyroïdie, H.Pylori/aspirine, dépistage CCR, grossesse/risque TDM, élinzanetant, gale
www.medicalement-geek.com
September 14, 2025 at 10:04 PM
#DragiWebdo n°495 : Infertilité, hypothyroïdie, H.Pylori/aspirine, dépistage CCR, grossesse/risque TDM, élinzanetant, gale
www.medicalement-geek.com/2025/09/drag...
www.medicalement-geek.com/2025/09/drag...
“The drug, Lynkuet, which contains the compound elinzanetant, adds to a limited number of nonhormonal treatment options… Doctors said it might also be better than previous nonhormonal options at treating menopause-related sleep issues, though that comparison has yet to be directly studied”
F.D.A. Approves New Menopause Drug
www.nytimes.com
October 24, 2025 at 10:22 PM
“The drug, Lynkuet, which contains the compound elinzanetant, adds to a limited number of nonhormonal treatment options… Doctors said it might also be better than previous nonhormonal options at treating menopause-related sleep issues, though that comparison has yet to be directly studied”
📰 The @fda.gov has granted priority review to elinzanetant for the treatment of moderate-to-severe vasomotor symptoms in patients receiving endocrine therapy for the management or prevention of HR+ breast cancer. #bcsm #oncology
Read more ➡️: www.onclive.com/view/fda-gra...
Read more ➡️: www.onclive.com/view/fda-gra...
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer | OncLive
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
www.onclive.com
September 28, 2026 at 8:11 PM
📰 The @fda.gov has granted priority review to elinzanetant for the treatment of moderate-to-severe vasomotor symptoms in patients receiving endocrine therapy for the management or prevention of HR+ breast cancer. #bcsm #oncology
Read more ➡️: www.onclive.com/view/fda-gra...
Read more ➡️: www.onclive.com/view/fda-gra...
The FDA approved a new nonhormonal menopause medication to treat hot flashes.
Here’s what you need to know about the drug:
Here’s what you need to know about the drug:
FDA approves a new drug for hot flashes. Here’s what to know about it.
The nonhormonal menopause medication called elinzanetant may give people more choices to manage hot flashes, experts say.
www.washingtonpost.com
October 30, 2025 at 11:01 AM
The FDA approved a new nonhormonal menopause medication to treat hot flashes.
Here’s what you need to know about the drug:
Here’s what you need to know about the drug:
Health Canada approves drug that treats hot flashes for use by breast cancer patients--Elinzanetant, also known by the brand name Lynkuet - made in Germany #Canada
www.ctvnews.ca/health/artic...
www.ctvnews.ca/health/artic...
Health Canada approves drug that treats hot flashes for use by breast cancer patients
Health Canada has authorized a drug to treat moderate to severe hot flashes and night sweats in breast cancer patients.
www.ctvnews.ca
August 20, 2026 at 4:25 PM
Health Canada approves drug that treats hot flashes for use by breast cancer patients--Elinzanetant, also known by the brand name Lynkuet - made in Germany #Canada
www.ctvnews.ca/health/artic...
www.ctvnews.ca/health/artic...
Women Leaders in Oncology: Tara Frenkl on Hope, Elinzanetant, and HER2+ Lung Cancer Advances
oncodaily.com/dialogues/31...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WomenLeaders #OncologyLeaders #LungCancer
oncodaily.com/dialogues/31...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WomenLeaders #OncologyLeaders #LungCancer
Women Leaders in Oncology: Tara Frenkl on Hope, Elinzanetant, and HER2+ Lung Cancer Advances - OncoDaily
Women Leaders in Oncology: Tara Frenkl on Hope, Elinzanetant, and HER2+ Lung Cancer Advances / ASCO, ASCO 2O25, cancer, OncoDaily, Oncology, Tara Frenkl,
oncodaily.com
June 25, 2025 at 2:12 PM
Women Leaders in Oncology: Tara Frenkl on Hope, Elinzanetant, and HER2+ Lung Cancer Advances
oncodaily.com/dialogues/31...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WomenLeaders #OncologyLeaders #LungCancer
oncodaily.com/dialogues/31...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WomenLeaders #OncologyLeaders #LungCancer
Experimental pill #elinzanetant reduced menopause hot flashes by 74% for a full year in a clinical trial. Non-hormonal option offers hope for women who can't use hormone therapy. Game-changing relief for disruptive symptoms. #MenopauseRelief
Experimental Pill, Elinzanetant, Treats Menopause Hot Flashes Without Hormones - Drugs.com MedNews
THURSDAY, Sept. 25, 2025 An experimental pill can significantly reduce hot flashes and night sweats for women after menopause, a new clinical trial has determin
www.drugs.com
September 25, 2025 at 7:06 PM
Experimental pill #elinzanetant reduced menopause hot flashes by 74% for a full year in a clinical trial. Non-hormonal option offers hope for women who can't use hormone therapy. Game-changing relief for disruptive symptoms. #MenopauseRelief
How are drugs developed? 💊 Let's break down the drug development process using elinzanetant, a non-hormonal treatment for moderate to severe vasomotor symptoms (hot flushes) associated with the menopause
#WomensHealth #PublicHealth #DrugDevelopment #Elinzanetant
#WomensHealth #PublicHealth #DrugDevelopment #Elinzanetant
February 25, 2026 at 5:05 PM
How are drugs developed? 💊 Let's break down the drug development process using elinzanetant, a non-hormonal treatment for moderate to severe vasomotor symptoms (hot flushes) associated with the menopause
#WomensHealth #PublicHealth #DrugDevelopment #Elinzanetant
#WomensHealth #PublicHealth #DrugDevelopment #Elinzanetant
Women’s health has long been ignored by pharmaceutical research. Not only are they less often included in clinical trials, but many exclusive female conditions are either not or barely researched.
👇@mapignorance.bsky.social
mappingignorance.org/2025/03/10/e...
👇@mapignorance.bsky.social
mappingignorance.org/2025/03/10/e...
Elinzanetant, a (possible) relief for menopausal hot flashes - Mapping Ignorance
Promising results of two randomised clinical trials testing a new drug, elinzanetant, for treating menopausal hot flashes
mappingignorance.org
March 10, 2025 at 7:41 PM
Women’s health has long been ignored by pharmaceutical research. Not only are they less often included in clinical trials, but many exclusive female conditions are either not or barely researched.
👇@mapignorance.bsky.social
mappingignorance.org/2025/03/10/e...
👇@mapignorance.bsky.social
mappingignorance.org/2025/03/10/e...
Menopoz tedavisinde kullanılan deneysel ilaç sıcak basmalarını %73 oranında azaltmaktadır.
Menopozla ilişkili semptomlar arasında sıcak basmaları, gece terlemeleri ve uyku bozuklukları yer almaktadır.
Elinzanetant, faz 3👇
Menopozla ilişkili semptomlar arasında sıcak basmaları, gece terlemeleri ve uyku bozuklukları yer almaktadır.
Elinzanetant, faz 3👇
Drug Reduces Hot Flashes by 73%, Trial Finds
The investigational drug elinzanetant reduced hot flashes and night sweats for post-menopausal women while improving quality of life.
newsroom.uvahealth.com
September 19, 2025 at 8:00 AM
Menopoz tedavisinde kullanılan deneysel ilaç sıcak basmalarını %73 oranında azaltmaktadır.
Menopozla ilişkili semptomlar arasında sıcak basmaları, gece terlemeleri ve uyku bozuklukları yer almaktadır.
Elinzanetant, faz 3👇
Menopozla ilişkili semptomlar arasında sıcak basmaları, gece terlemeleri ve uyku bozuklukları yer almaktadır.
Elinzanetant, faz 3👇
In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results: nej.md/3FnKwU7
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
June 2, 2025 at 12:09 PM
In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results: nej.md/3FnKwU7
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
Whether the neurokinin-targeted therapy elinzanetant is effective in treating vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer is unclear. Research findings from the OASIS-4 phase 3 trial are summarized in a new Quick Take video. nej.md/47FjcMR
August 22, 2025 at 7:02 PM
Whether the neurokinin-targeted therapy elinzanetant is effective in treating vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer is unclear. Research findings from the OASIS-4 phase 3 trial are summarized in a new Quick Take video. nej.md/47FjcMR
Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive. Fatima Cardoso presents new findings at #EBCC15 @BreastEuropean: event.eortc.org/ebcc15/2026/...
Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive - EBCC 15
Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive
event.eortc.org
March 26, 2026 at 12:46 PM
Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive. Fatima Cardoso presents new findings at #EBCC15 @BreastEuropean: event.eortc.org/ebcc15/2026/...
Non-hormonal hot-flash remedies gives options to women, experts say. There are limited choices for people going through #menopause who do not want hormone therapy or are not eligible for it, by Lindsey Bever www.washingtonpost.com/wellness/202... via @washingtonpost.com #cancer #HRT
This nonhormonal hot-flash remedy gives options to women, experts say
Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.
www.washingtonpost.com
May 31, 2025 at 9:40 PM
Non-hormonal hot-flash remedies gives options to women, experts say. There are limited choices for people going through #menopause who do not want hormone therapy or are not eligible for it, by Lindsey Bever www.washingtonpost.com/wellness/202... via @washingtonpost.com #cancer #HRT
“Searching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?”
authors.elsevier.com/a/1kG5d9UKeT...
authors.elsevier.com/a/1kG5d9UKeT...
authors.elsevier.com
December 15, 2024 at 7:47 PM
“Searching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?”
authors.elsevier.com/a/1kG5d9UKeT...
authors.elsevier.com/a/1kG5d9UKeT...
Exciting to see this data for elinzanetant improving vasomotor symptoms (and sleep and menopause related quality of life) in patients with breast cancer on endocrine therapy!
www.bayer.com/media/en-us/...
www.bayer.com/media/en-us/...
www.bayer.com
January 11, 2025 at 5:01 PM
Exciting to see this data for elinzanetant improving vasomotor symptoms (and sleep and menopause related quality of life) in patients with breast cancer on endocrine therapy!
www.bayer.com/media/en-us/...
www.bayer.com/media/en-us/...
Gran noticia para cuando me convierta en tortuga ninja: han dado con una posible medicación para aliviar los sofocos.
Elinzanetant, a (possible) relief for menopausal hot flashes - Mapping Ignorance
Promising results of two randomised clinical trials testing a new drug, elinzanetant, for treating menopausal hot flashes
mappingignorance.org
March 28, 2025 at 8:30 AM
Gran noticia para cuando me convierta en tortuga ninja: han dado con una posible medicación para aliviar los sofocos.
New medicines added to the PrEP drug interaction checker: Aficamten, Cladribine (injection), Cladribine (oral), Clofarabine, Elinzanetant, Gepotidacin, Milsaperidone, Orforglipron, Pentostatin, Suvorexant, Suzetrigine, Tradipitant, Vorapaxar, Zavegepant, Zoliflodacin. That's 1155 medicines in total
September 24, 2026 at 8:38 AM
New medicines added to the PrEP drug interaction checker: Aficamten, Cladribine (injection), Cladribine (oral), Clofarabine, Elinzanetant, Gepotidacin, Milsaperidone, Orforglipron, Pentostatin, Suvorexant, Suzetrigine, Tradipitant, Vorapaxar, Zavegepant, Zoliflodacin. That's 1155 medicines in total
New pill eases hot flashes, night sweats
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause
This randomized clinical trial examines 52-week efficacy and safety of elinzanetant in treating moderate to severe vasomotor symptoms that are associated with menopause.
jamanetwork.com
September 20, 2025 at 9:39 PM
New pill eases hot flashes, night sweats
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
“Elinzanetant” sounds like a cockney flower seller & the Israeli prime minister had a baby.
January 10, 2024 at 7:18 PM
“Elinzanetant” sounds like a cockney flower seller & the Israeli prime minister had a baby.